Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lidakol n-docosanol 10 percent cream: Began enrolling Canadian patients in a 750-patient Phase III trial that is underway in the U.S.

Lidak Pharmaceuticals (LDAKA),

Read the full 35 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE